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Abstract 
In a recent review article titled “A new look at cerebrospinal fluid circulation”, Brinker et al. comprehensively described 
novel insights from molecular and cellular biology as well as neuroimaging research, which indicate that cerebro-
spinal fluid (CSF) physiology is much more complex than previously believed. The glymphatic system is a recently 
defined brain-wide paravascular pathway for CSF and interstitial fluid exchange that facilitates efficient clearance 
of interstitial solutes, including amyloid-β, from the brain. Although further studies are needed to substantiate the 
functional significance of the glymphatic concept, one implication is that glymphatic pathway dysfunction may con-
tribute to the deficient amyloid-β clearance in Alzheimer’s disease. In this paper, we review several lines of evidence 
suggesting that the glymphatic system may also have potential clinical relevance for the understanding of glaucoma. 
As a clinically acceptable MRI-based approach to evaluate glymphatic pathway function in humans has recently 
been developed, a unique opportunity now exists to investigate whether suppression of the glymphatic system 
contributes to the development of glaucoma. The observation of a dysfunctional glymphatic system in patients with 
glaucoma would provide support for the hypothesis recently proposed by our group that CSF circulatory dysfunction 
may play a contributory role in the pathogenesis of glaucomatous damage. This would suggest a new hypothesis for 
glaucoma, which, just like Alzheimer’s disease, might be considered then as an imbalance between production and 
clearance of neurotoxins, including amyloid-β.
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Background
In a recent review article titled “A new look at cerebro-
spinal fluid circulation” published in Fluids and Barriers 
of the CNS, Brinker et al. [1] comprehensively described 
novel insights from molecular and cellular biology as 
well as neuroimaging research, which indicate that cer-
ebrospinal fluid (CSF) physiology is much more complex 
than previously believed. According to the traditional 
understanding of CSF physiology, the majority of CSF is 
produced by the choroid plexus, circulates through the 
ventricles, the cisterns, and the subarachnoid space (SAS) 
ultimately to be absorbed into the venous blood system 
across arachnoid villi and/or via perineural spaces of the 
cranial nerves into the cervical lymphatics [1]. Recently, 
the classic CSF circulation theory has been increasingly 
challenged and a new hypothesis regarding CSF hydrody-
namics has been proposed [1, 2]. According to this new 
hypothesis, CSF is permanently produced and absorbed 
inside the whole CSF system, as a consequence of fil-
tration and reabsorption of water volume through the 
capillary walls into the interstitial fluid (ISF) of the sur-
rounding brain tissue [1–3]. Furthermore, recent evi-
dence has revealed the existence of a brain-wide network 
of paravascular channels, termed the “glymphatic” path-
way, along which a large proportion of subarachnoid CSF 
recirculates through the brain parenchyma, facilitating 
the clearance of interstitial solutes, including amyloid-β 
(Aβ), from the brain [1, 4]. Although these concepts 
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substantiate their functional significance [1], one implica-
tion is that glymphatic pathway dysfunction may contrib-
ute to the deficient Aβ clearance in the pre-clinical stages 
of Alzheimer’s disease (AD) [5]. AD is thought to be 
caused by an imbalance between production and clear-
ance of Aβ, leading to Aβ accumulation in the brain [6]. 
The new insights into the physiology of CSF circulation 
could also open new possibilities in the understanding of 
other neurodegenerative diseases in which the mis-accu-
mulation of neurotoxic depositions contributes to disease 
development [1, 4]. In this paper, we review several lines 
of evidence showing that glaucoma may be an attractive 
candidate for such a disease. Interestingly, MRI-based 
imaging now provides a unique opportunity for investi-
gating the role of the glymphatic system in glaucoma. If 
confirmed, this could lead to a new understanding of the 
pathogenesis of glaucoma.
Discussion
Glaucoma is a complex neurodegenerative disease
Glaucoma is one of the leading causes of irreversible 
blindness worldwide [7]. Primary open-angle glaucoma 
(POAG), the most common type, is a complex neuro-
degenerative disease characterized by slow progressive 
degeneration of retinal ganglion cells (RGCs) and their 
axons in the optic nerve, resulting in structural changes 
in the optic nerve head and corresponding visual field 
defects [7]. The optic nerve head is the likely site of ini-
tial injury and raised intraocular pressure (IOP) is con-
sidered a major risk factor for the development of POAG 
[7, 8]. However, elevated IOP is not present in all forms 
of POAG [7]. Indeed, in normal-tension glaucoma, IOP 
is not elevated and thus other risk factors must also be 
involved in the optic neuropathy of POAG [7].
Growing evidence in the literature provides strong sup-
port for the concept that the CSF (both its pressure and 
composition) surrounding the optic nerve may have fun-
damental significance in the pathogenesis of glaucoma 
[9–12]. The optic nerve, a white matter tract of the central 
nervous system (CNS), is ensheathed in all three menin-
geal layers and surrounded by CSF in the SAS with a pres-
sure equivalent to intracranial pressure (ICP) [10, 13]. 
Therefore, in addition to IOP, the optic nerve is exposed 
to the ICP [10]. The lamina cribrosa, the perforated region 
of the sclera through which the nerve fibers of the optic 
nerve pass as they exit the eye, separates these two pres-
surized regions [10]. The structures of the eye considered 
in this Commentary are illustrated in Figure 1.
Accumulation of Aβ may be involved in RGC death 
in glaucoma
Considerable evidence indicates that Aβ may be impli-
cated in the development of RGC apoptosis in glaucoma 
[14–17], suggesting a possible link with AD. Previous 
findings showed that there is IOP-sensitive increase in Aβ 
in glaucoma [14–17]. McKinnon et al. [14] reported that 
rat RGCs subjected to chronic elevation of IOP exhibit 
caspase-3-mediated abnormal processing of β-amyloid 
precursor protein (APP) with increased expression of Aβ. 
This suggested a new hypothesis for RGC death in glau-
coma involving chronic Aβ neurotoxicity, mimicking AD 
at the molecular level [15]. Activation of caspases and 
abnormal APP processing, which includes production 
of Aβ, are also important events in AD [14]. Guo et  al. 
[16] provided further evidence that Aβ is a likely media-
tor of pressure-induced RGC death. In a rat model mim-
icking chronic ocular hypertension, the authors found 
that Aβ colocalized with apoptotic RGCs [16]. They also 
demonstrated in  vivo that Aβ induced significant RGC 
apoptosis [16]. The authors further provided evidence 
that targeting Aβ and blocking its effects with combina-
tion therapy may represent an effective treatment strat-
egy in glaucoma [16]. Recently, in a study using monkeys 
with experimental glaucoma, Ito et  al. [17] found time-
dependent expressions and localization of Aβ in the ret-
ina as well as in the optic nerve head after chronic IOP 
elevation. It is interesting to note that a number of stud-
ies have similarly reported increased retinal Aβ in both 
AD transgenic mice and in human postmortem retinas of 
AD patients [18, 19].
Decreased Aβ and increased tau in vitreous fluid and CSF
Studies consistently report decreased levels of Aβ (1–42) 
and increased levels of tau in CSF from AD patients in 
comparison with healthy subjects [20, 21]. Among AD 
patients, the consistent finding of low concentrations of 
Aβ (1–42) in CSF compared with those of age-matched 
controls is thought to be due to increased aggregation, 
fibril and plaque formation, with decreased clearance of 
these peptides from the CNS [22]. To test the idea that 
Aβ (1–42) and tau contribute to the development of glau-
coma, Yoneda et  al. [21] measured Aβ (1–42) and tau 
concentrations in vitreous fluid samples from eyes from 
patients with glaucoma. The authors found significantly 
decreased vitreous levels of Aβ (1–42) (consistent with 
Aβ deposition in the retina) and significantly increased 
vitreous levels of tau in patients with glaucoma in com-
parison with the levels in a control group [16, 21]. Their 
findings suggested that the neurodegenerative pro-
cesses in glaucoma might share, at least in part, a com-
mon mechanism with AD [21]. It is also interesting to 
note that in a recent report, Nucci et  al. [23] described 
a glaucoma patient with medically controlled IOP who 
experienced disease progression concomitantly with the 
onset of mild cognitive impairment and positivity for 
CSF markers of AD (decreased Aβ and elevated levels of 
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total and phosphorylated tau). The authors suggested the 
possibility that altered CSF circulatory dynamics in this 
case reduced neurotoxin clearance along optic nerves in 
the SAS and that deposits/aggregates of tau and/or other 
toxic molecules may have contributed to the glaucoma 
progression.
Flow of fluids in the anterior part of the optic nerve
With regard to the viewpoint presented here, it is inter-
esting to note that previous studies investigating the 
flow of fluids in the anterior part of the optic nerve seem 
to confirm that there is at least some level of exchange 
between the ISF of the optic nerve and the surrounding 
CSF. These studies also demonstrated that the fluids from 
the vitreous body and the optic nerve move from oppo-
site directions and converge at the optic nerve head [24, 
25]. Interestingly, as noted above, in glaucoma, the optic 
nerve head is recognized as the likely site of initial injury 
[8].
In these investigations, electron microscopic studies 
and a variety of tracer substances were used [24]. The 
probable sources of ISF in the anterior part of the optic 
nerve were found to be capillaries in the nerve itself, peri-
papillary choroid, vitreous, CSF and possibly axoplasm 
in the local axons [24]. First of all, several studies found 
that there is a backward bulk flow of fluid from the vitre-
ous into the optic nerve head [24–26]. Rodriguez-Peralta 
[25] investigated the subject in rabbits, cats, dogs, guinea 
pigs, and rhesus monkeys by injecting diaminoacridine 
dyes into the vitreous. The groups of animals receiving 
the tracer intravitreally showed that these compounds 
moved promptly peripherally toward the retina and nota-
bly toward the optic nerve head [25]. Bright fluorescence 
was found in the deeper layers of the retina and par-
ticularly in the optic nerve head, anterior to the lamina 
cribrosa [25]. The latter was the area of the highest con-
centrations of diaminoacridines [25]. Peyman and Apple 
[26] injected horseradish peroxidase into the vitreous 
of squirrel monkeys. They found that the tracer perme-
ated readily into the optic nerve head and diffused freely 
through intercellular spaces of astrocytes, along collagen 
septa of the nerve and perivascular spaces [26]. There 
was no diffusion into capillaries of the nerve [26]. Hayreh 
[24] studied this backward flow from the vitreous along 
the optic nerve in rhesus monkeys by injecting tritiated 
leucine into the vitreous. The RGCs and the inner part 
of the retina had been first infarcted so that no axoplas-
mic transport was present [24]. Thus, the tracer seen in 
the optic nerve head represented a direct flow from the 
vitreous into the nerve, with no axoplasmic transport 
Figure 1 Section of eye, optic nerve head and brain, illustrating the subarachnoid space. The lamina cribrosa (green) is a sieve-like structure in the 
posterior part of the sclera and allows the passage of the retinal ganglion cell axons and the central retinal vessels. The optic nerve is surrounded by 
cerebrospinal fluid (blue) in the subarachnoid space. The enlarged histologic view is modified and reproduced with permission, Boston University 
Histology Learning System (Deborah W. Vaughan, PhD).
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[24]. These studies revealed a heavy accumulation of the 
tracer in the glial cells in the anterior part of the prelami-
nar region, less accumulation in the posterior part of the 
prelaminar region, much less in the lamina cribrosa, and 
none or minimal accumulation in the retrolaminar optic 
nerve [24]. In addition to this backward bulk flow of fluid 
from the vitreous into the optic nerve head, several stud-
ies established that there is a flow of fluid from the SAS 
of the optic nerve into the optic nerve and optic nerve 
head [24, 25, 27, 28]. Rodriguez-Peralta [25] injected 
diaminoacridine dyes in the cisterna magna of rabbits, 
cats, dogs, guinea pigs, and rhesus monkeys. After 1  h, 
the dye was heavily concentrated in the SAS of the optic 
nerve and had diffused into the optic nerve and optic 
nerve head [25]. It was not found in the retina or vitreous 
body [25]. Tsukahara and Yamashita [27] injected horse-
radish peroxidase into the lateral ventricles of mice. 15 
and 45 min later, the tracer was found in the SAS of the 
optic nerve [27]. It also penetrated freely into the optic 
nerve, and could be traced along the intercellular space 
between glial cells and optic nerve fibers and connective 
tissue septa, extending as far forward as the prelaminar 
region [27]. In his studies on rhesus monkeys, Hayreh 
[28] injected sodium fluorescein into the cisterna magna. 
On fluorescence photography of the optic disc in the liv-
ing animal, usually within half an hour after the injection 
of the dye, the disc developed progressively increasing 
intense fluorescence and in 1.5–2  h it even started to 
diffuse into the vitreous [28]. Histological examination 
showed fluorescence of these tissues of the optic nerve 
and optic nerve head except in the lumen of vessels [28].
Glymphatic pathway for CSF‑ISF exchange in the optic 
nerve?
Taken together, the above findings at least suggest some 
level of exchange between the ISF of the optic nerve and 
the surrounding CSF. Compared to the brain size, the 
optic nerve is a relatively small structure. In such small 
structures, simple diffusion of even large solutes may 
be sufficiently rapid to allow clearance (Iliff JJ, personal 
communication, 2013). However, apart from simple dif-
fusion or conventional CSF bulk flow, the question is 
whether the optic nerve also uses paravascular pathways 
to facilitate more rapid exchange. Figure 2 is a schematic 
depiction of the glymphatic pathway in the brain. As an 
extension of the brain (Figure 1), the eye displays remark-
able similarities to the brain in terms of anatomy and 
functionality [13]. Therefore, it would be very interest-
ing to investigate whether a similar glymphatic pathway 
for CSF-ISF exchange exists in the optic nerve. However, 
even if this is not the case, there may be an interconnec-
tion between the glymphatic pathway of the brain and 
the SAS of the optic nerve, which in turn may facilitate 
efficient CSF-ISF exchange in the optic nerve, allowing 
clearance of interstitial solutes, including Aβ. Explor-
ing this possibility could shed new light on the patho-
genesis of glaucoma, and introduce a new look at the 
disease. Indeed, if confirmed, one might expect that a 
dysfunctional glymphatic system of the brain could ulti-
mately result in reduced neurotoxin clearance in the 
optic nerve and lead to glaucomatous neurodegeneration. 
The observation of a dysfunctional glymphatic system in 
patients with glaucoma would also provide support for 
the hypothesis recently proposed by our group [7] that 
CSF circulatory dysfunction may play a contributory role 
in the pathogenesis of glaucomatous damage. Our view-
point argues that glaucoma, just like AD, may occur when 
there is an imbalance between production and clearance 
of neurotoxins, including Aβ [30]. Our hypothesis is that 
the dominant alteration determines whether glaucoma 
manifests as normal-tension glaucoma or as high-tension 
glaucoma. In normal-tension glaucoma, abnormal clear-
ance of Aβ from the optic nerve may predominate as a 
result of glymphatic pathway dysfunction. In high-ten-
sion glaucoma, IOP-induced Aβ generation may predom-
inate and even mild impairment of glymphatic pathway 
function may result in glaucomatous optic nerve damage.
Interestingly, a growing body of evidence indicates 
that ICP is lower in patients with POAG when compared 
with nonglaucomatous control subjects and additionally, 
is lower in the normal-tension versus the high-tension 
Figure 2 Schematic depiction of the glymphatic pathway in the 
brain. In this brain-wide pathway, cerebrospinal fluid from the suba-
rachnoid space rapidly enters the brain along paravascular channels 
surrounding penetrating arteries and exchanges with brain interstitial 
fluid (ISF). ISF and parenchymal solutes (e.g., Aβ) are cleared from the 
brain along paravenous routes. The green arrow has been added as a 
reminder that fluid secreted by the blood–brain barrier contributes 
to the fluid in the parenchyma. Reproduced with permission from 
Hladky and Barrand [29], their Figure 9a (the glymphatic proposal).
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form of POAG [9–11]. A decreased ICP can be the con-
sequence of decreased CSF production or reduced resist-
ance to CSF outflow. Indeed, the ICP is built up by the 
equilibrium between the production and outflow of CSF 
[7]. In this context, it is important to note that a recent 
study found that ICP decreases significantly and steadily 
after age 50 [31]. This parallels the rise in prevalence of 
glaucoma with increasing age [31]. There is no reported 
evidence that CSF outflow resistance decreases with 
age, rather most studies report CSF outflow resistance 
increases [31, 32]. However, there is evidence that the 
CSF production decreases with age [31, 33]. Therefore, 
the lower ICP reported in POAG patients could be an 
indicator of decreased CSF production and turnover [7]. 
Given that ICP is lower in patients with normal-tension 
glaucoma compared to patients with high-tension glau-
coma, these changes in CSF circulatory physiology may 
be even more pronounced in the normal-tension com-
pared to the high-tension form of POAG.
Also interestingly, the present viewpoint raises the pos-
sibility of explaining the clinical overlap of AD and glau-
coma. Several studies have found an increased prevalence 
of glaucoma among patients with AD [34, 35]. In a nurs-
ing home-based study in Germany, Bayer et al. [34] studied 
112 patients with AD and 116 control subjects. The preva-
lence of POAG was reported to be 25.9% in patients with 
AD and 5.2% in the control group. Glaucomatous visual 
field loss and/or optic disc cupping were the criteria for 
the diagnosis of glaucoma. In a Japanese study, Tamura 
et  al. [35] found a prevalence of POAG of 23.8% among 
172 patients with AD, which was significantly higher than 
the 9.9% among 176 control subjects. This higher rate of 
glaucoma among AD patients in combination with the 
multiple intriguing similarities between these two dis-
eases has raised the question of whether AD and glaucoma 
may share a common underlying mechanism [36]. Glym-
phatic pathway dysfunction as a potential mechanistic link 
between AD and glaucoma is an attractive hypothesis since 
this could explain the coincidence of the two disorders.
Obviously, future studies are needed to elucidate the 
potential role of the glymphatic system in glaucoma. 
Interestingly, a recent study showed that the glymphatic 
system can be evaluated in the live rat brain using con-
trast-enhanced MRI following intracisternal gadolinium-
based contrast infusion [37]. However, intracisternal 
infusions are rarely used in a clinical setting due to their 
high risk for developing iatrogenic complications, includ-
ing traumatic tissue injury [38]. In contrast, the lumbar 
intrathecal route of administration is now commonly 
used in CT-myelography, anesthesia, pain management 
and chemotherapy [38]. Importantly, a recent pre-clin-
ical study reported that perivascular CSF-ISF exchange 
within the rat brain can be evaluated following infusion of 
CSF tracer via a lumbar, in addition to an intracisternal, 
route [38]. The authors concluded that lumbar intrathecal 
contrast delivery is a clinically useful approach that could 
be used in conjunction with dynamic contrast-enhanced 
MRI nuclear imaging to assess glymphatic pathway func-
tion in humans [38]. This now provides a unique oppor-
tunity to evaluate whether suppression of the glymphatic 
system and thus CSF circulatory failure contributes to 
the development of glaucoma.
Conclusion
Novel insights from molecular and cellular biology as 
well as neuroimaging research indicate that CSF physi-
ology is much more complex than previously believed. 
The glymphatic system is a recently defined brain-wide 
paravascular pathway for CSF-ISF exchange that facili-
tates efficient clearance of interstitial solutes, including 
Aβ, from the brain. A newly developed theory proposes 
that failure of this clearance system underlies increased 
Aβ brain accumulation in AD. In this paper, we have 
reviewed several lines of evidence suggesting that the 
glymphatic system may also have potential clinical rel-
evance for the understanding of glaucoma. It should 
be stressed that for the moment at least, the present 
hypothesis remains unproven. Future studies are needed 
to determine whether the glymphatic system may play 
a pathogenic role in the development of glaucoma. As 
a clinically acceptable MRI-based approach to evaluate 
glymphatic pathway function in humans has recently 
been developed, a unique opportunity now exists to 
investigate whether suppression of the glymphatic system 
and thus CSF circulatory dysfunction contributes to the 
development of glaucoma.
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